Abbvie Inc ABBV:NYSE

Last Price$154.78NYSE Previous Close - Last Trade as of 7:00PM ET 5/17/22

Today's Change-0.69(0.44%)
Bid (Size)$154.80 (1)
Ask (Size)$156.00 (1)
Day Low / High$152.85 - 155.79
Volume6.0 M

View Pharmaceuticals: Major IndustryPeer Comparison as of 05/17/2022


Abbvie Inc ( NYSE )

Price: $154.78
Change: -0.69 (0.44%)
Volume: 6.0 M
7:00PM ET 5/17/2022

Pfizer Inc ( NYSE )

Price: $51.34
Change: +0.67 (1.32%)
Volume: 19.9 M
7:00PM ET 5/17/2022

Eli Lilly and Co ( NYSE )

Price: $301.40
Change: +2.02 (0.67%)
Volume: 2.6 M
7:00PM ET 5/17/2022

Merck & Co Inc ( NYSE )

Price: $93.00
Change: +0.68 (0.74%)
Volume: 17.6 M
7:00PM ET 5/17/2022

Bristol-Myers Squibb Co ( NYSE )

Price: $78.22
Change: +1.31 (1.70%)
Volume: 14.5 M
7:00PM ET 5/17/2022

Read more news Recent News

Berkshire Hathaway Divests Wells Fargo Stake, Picks Up Citi Shares in Portfolio Reshuffle
4:11PM ET 5/17/2022 MT Newswires

Berkshire Hathaway (BRK.A) has divested all of its shares in Wells Fargo (WFC), Bristol Myers Squibb (BMY) and AbbVie (ABBV) as of March 31, while picking...

AbbVie Receives Option to License Worldwide Rights to Cugene's CUG252 for Autoimmune, Inflammatory Diseases
10:13AM ET 5/16/2022 MT Newswires

AbbVie (ABBV) said Monday it is working with biotechnology startup Cugene, under which it has agreed to receive the option to license worldwide rights to...

AbbVie Says Its Crohn's Disease Therapy Performed 'Significantly' Better Than Placebo in Phase 3 Maintenance Study
10:45AM ET 5/11/2022 MT Newswires

AbbVie (ABBV) said Wednesday its upadacitinib oral therapy for adults with moderate to severe Crohn's disease showed "significantly higher" endoscopic...

Research Alert: CFRA Keeps Buy Opinion On Shares Of Abbvie Inc.
1:35PM ET 5/02/2022 MT Newswires

CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as...

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Number of Employees30,000
Recent SEC Filing05/13/20224
Chairman & Chief Executive OfficerRichard A. Gonzalez
President & Vice Chairman-Management BoardMichael E. Severino
CFO, Vice Chairman-Finance & Commercial OperationsRobert A. Michael
Chief Scientific Officer, Senior VP-R&DThomas J. Hudson

Company Highlights

Price Open$155.38
Previous Close$155.47
52 Week Range$105.56 - 175.91
Market Capitalization$273.5 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 3.63%
Dividend Ex-Date04/13/2022
Dividend Pay-Date05/16/2022
Dividend Yield 5 Year Average4.08%
Next Earnings Announcement07/29/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings22.02
Earnings per Share$8.17
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin21.86%
Return on Equity85.78%

Analyst Ratings as of 05/04/2022

Consensus RecommendationConsensus Icon
Powered by Factset